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Abstract
Background:  The aim of this study is to comparatively elucidate the underlying molecular
pathways and clinicopathological criteria in schistosomal bladder tumor (SBT) versus non-
schistosomal bladder tumor (NSBT).
Methods: This study explored the role of p53, p16, bcl-2, ki-67, c-myc, Rb and EGFR, by using
Immunohistochemistry assay, in 45 SBT and 39 NSBT patients in comparison with 16 schistosomal
chronic cystitis (SC), 28 non-schistosomal chronic cystitis (NSC), and 20 normal control (CTL)
subjects. The studied markers in SBT and NSBT were correlated with different clinicopathological
criteria namely, tumor histopathology, grading, invasiveness, stage, and presentation of the disease.
Results: SBT was associated with high grade invasive squamous cell carcinoma (SCC) while NSBT
was associated with lower grade less invasive transitional cell carcinoma (TCC). The expression of
p53, bcl-2, c-myc, and EGFR was higher in SBT than in NSBT while Rb was higher in NSBT than in
SBT. However, p16 and ki-67 were not different between SBT and NSBT. The profile of molecular
markers in SC was similar to NSC except for EGFR which was higher in SC than in NSC. Both SC
and NSC showed higher level of p53, bcl-2, ki-67, and EGFR than in CTL group while p16, Rb, and
c-myc were not different. p53 was associated with high grade SCC in both SBT and NSBT. Bcl-2
was associated with high grade invasive tumors in SBT and NSBT. P16 was associated with low
grade, late stage, and recurrent SBT and high grade, invasive, late stage, and recurrent NSBT. Rb
was associated with SCC in SBT, invasive tumors in NSBT, and late stage and recurrent
presentation in both SBT and NSBT. C-myc was associated with high grade, invasive, and late stage
SBT and SCC, high grade, invasive, and late stage NSBT. EGFR was associated with invasive SCC in
SBT and invasive, high grade, and late stage TCC in NSBT. ki-67 was associated with invasive SBT
and high grade late stage NSBT.
Conclusion:  SBT and NSBT showed distinct molecular profile of tumor development and
progression which can be taken into consideration in fine adjusting the anti-cancer therapy for SBT
and NSBT.
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Introduction
Bladder cancer is the second most common malignancy of
the genitourinary system in both males and females [1].
The most common type diagnosed in North America,
South America, Europe, and Asia is transitional cell carci-
noma (TCC), which is mainly non-schistosomal bladder
tumors (NSBT), followed by squamous cell carcinoma
(SCC) which is found more in geographical regions where
schistosomiasis is prevalent [1]. The neoplastic changes in
the urothelium of bladder is a multistep phenomenon
[2]. The exact genetic events leading to urothelial transfor-
mation involve the activation of oncogenes, inactivation
or loss of tumor suppressor genes, and alterations in the
apoptotic gene products [3].
One of the conditions leads to bladder cancer in Africa,
the Middle East, and Asia is schistosomiasis [4,5]. S. hae-
matobium is the most predominant species in the Middle
East, Asia, and Africa and the most implicated in the schis-
tosomal bladder tumors (SBT) in these regions [6,7].
C-myc is implicated in bladder cancer, the genetic mecha-
nism causing overexpression of the c-myc gene in bladder
cancer is unknown. It could be related to hypomethyla-
tion [8] and its overexpression has been shown to be asso-
ciated with high-grade bladder cancer [9]. Another
oncogene implicated in bladder cancer, namely epidermal
growth factor receptor (EGFR). Overexpression of EGFR
has been described in several solid tumors including blad-
der, breast, colorectal, prostate, and ovarian cancers [10].
And 70% of muscle-invasive bladder cancers express
EGFR, which is associated with poor prognosis [11].
The majority of aggressive and invasive bladder carcino-
mas have alterations in the tumor suppressor genes prod-
ucts such as retinoblastoma (Rb) [12]. A study revealed
that tumor expression of Rb proteins in locally advanced
bladder cancers was found abnormal [13]. Another tumor
suppressor protein, p53, plays a vital role in the regulation
of cell cycle. The defective p53 in human cancer leads to
the loss of p53-dependent apoptosis, proliferative advan-
tage, genomic instability and DNA repair and angiogenic
control loss [14]. Mutations in the p53 gene result in the
production of dysfunctional protein product with a pro-
longed half-life compared to the wild-type protein [14].
On the other hand, p16, which is a tumor suppressor pro-
tein, was found almost abnormal in the advanced bladder
cancers where it was severely lowered and impaired in
function. [12].
Overexpression of bcl-2 has been reported in a wide vari-
ety of cancers including prostate, colorectal, lung, renal,
bladder and leukemia [15]. Several studies have provided
conclusive evidence that elevations in bcl-2 expression
cause resistance to chemotherapy and radiotherapy and
increases the proliferation [16]. On the other hand, Ki 67
is used to evaluate the proliferative potential of any tumor
as it is one of the important markers for cell proliferation
[17].
There was no previous study explored the profiling of
molecular markers in SBT and NSBT with respect to tumor
suppressor proteins: p53, Rb, and p16, oncogenes: c-myc,
and EGFR, an antiapoptotic protein: bcl-2, and a prolifer-
ative protein, ki-67 together in one study. Moreover, c-
myc, EGFR, and Rb have not been investigated thoroughly
in relation to SBT. In addition, this study compared the
profile of the studied markers among SBT, NSBT, chronic
schistosomal cystitis (SC), chronic non-schistosomal cys-
titis (NSC), and normal control subjects (CTL). This study
is believed to highlight the essential molecular targets that
can be important candidates for anti-cancer therapy in
both SBT and NSBT.
Materials and methods
The population of the study
Bladder cancer patients
Eighty four (84) patients (63 men and 21 women) with
bladder cancer, confirmed by histopathology, were
included in this study in the period from March 2007 to
May 2008. The patients with bladder cancer were
retrieved, examined, interviewed, and sampled in the
region of The Middle East (Jordan, Syria and Iraq). The
investigational study was conducted in the University
Putra Malaysia (UPM) in Malaysia. The patients' age
ranged 38–72 years old with mean age 59.49 ± 5.7 years.
The involved patients were selected from 3 central teach-
ing hospitals without bias to age, sex, or cancer pathology.
The involved patients were sampled before the beginning
of anti-cancer therapy. The diagnosis of bladder cancer
was established by doing urine cytology and diagnostic
cyctoscopy where the histopathology of biopsies con-
firmed the diagnosis of bladder cancer and determined
the tumor grade, local invasiveness, and the histopatho-
logical type of cancer. The tumor spread and metastasis
was assessed by CT scans and cystoscopy.
Moreover, past schistosomal infection was monitored by
retrieving the previous medical records. The current diag-
nosis of schistosomiasis was done by cystoscopy through
finding bilharzial granuloma or egg in histopathological
sections. Accordingly, patients with bladder cancer were
categorized into 45 patients with SBT and 39 patients with
NSBT. The involved patients with bladder cancer did not
show extra-bladder tumors. The stages of the retrieved
patients ranged from I to IV.
Moreover, cancer patients were categorized accordingly
into muscle invasive (T2, T3, and T4) and non invasive
tumors (Ta, T1, and CIS). For comparative purposes withJournal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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previous reports, the 1973 WHO grading system (papil-
loma, G1, G2 or G3) was used in this study which is still
the most commonly used system despite being super-
seded by the 2004 WHO. The retrieved tumors were histo-
logically categorized as low grade (grades 1–2) and high
grade (grade 3). Moreover, the tumor morphology was
categorized by cystoscopy into 71 cases papillary, 12 cases
sessile and 1 case nodular. Written consents were granted
by the involved subjects for sampling. The handling with
human subjects was done under the permission of the
regional committee of Ethics for biomedical research.
The group of benign bladder lesions
This group encompassed 44 untreated cases of chronic
cystitis patients (29 men and 15 women) with mean age
57.62 ± 3.78 years. The patients with chronic cystitis were
retrieved and sampled from the same geographical region
of cancer patients, the Middle East. Patients with chronic
cystitis were diagnosed by urine cytology and diagnostic
cystoscopy coupled with histopathological examination.
There were no signs of premalignant lesions (squamous
metaplasia, dysplastic changes, or leukoplakia) nor were
signs of prostatic enlargement found. Under the same
diagnostic protocols done for bladder cancer patients, the
chronic cystitis patients were grouped into 16 schisto-
somal cystitis (SC) patients and 28 non-schistosomal cys-
titis (NSC) patients.
Control group
Twenty age- and sex- matched individuals (12 men and 8
women) at mean age 58.3 ± 6.1 years old were involved
from the Middle East region. Their bladders were investi-
gated by routine cystoscopy and biopsies were taken. They
were found free of bladder cancer or any other bladder
disease or inflammation, therefore, they were considered
as control group (CTL).
Processing of biopsies
The bladder cancer patients, the chronic cystitis patients,
and CTL subjects underwent transurethral resection of
bladder tumor (TUR-BT), cystitis tissues, and normal
mucosal tissues respectively. The retrieved specimens were
composed of multiple pieces, 2–5 mm in thickness. Spec-
imens were immersed in 10% formalin in order to make
a paraffin block. The histopathological paraffin blocks of
biopsies were sectioned into 4 um thick sections. Hema-
toxylin and Eosin slides were prepared and examined by a
histopathologist for confirming the histopathological
diagnosis, the grade, and the invasiveness of the tumor. A
set of steps were pursued under the supervision of a
pathologist to minimize as could as possible the fixation-
related loss of target proteins. These steps were: minimal
prefixation time of 1 hour, the use of cold 4% paraformal-
dehyde and cold fixation at 4°C, and short duration of fix-
ation up to 5 hours [18]. Moreover, the paraffin-
embedded sections processed for immunohistochemistry
(IHC) assay were examined in a period not more than 3
days. It was stated that insignificant loss of nucleic acids or
proteins was observed within the first 3 days of fixation-
paraffin embedding [18].
Immunohistochemistry assay
Antibodies
IHC staining was conducted using a set of mouse mono-
clonal antibodies; anti-p53, anti-p16, anti bcl-2, and anti-
c-myc (InnoGenex, USA) and anti Ki-67, anti-Rb-1, and
anti-EGFR (DakoCytomation). Secondary biotinylated
goat anti-mouse antibodies were used (DakoCytoma-
tion). Antibodies were diluted in the recommended anti-
body diluting buffer (Dako). The working dilutions and
the final concentrations of the primary antibodies were
1:100 and 0.005 mg/mL for anti-p53, 1:120 and 0.008
mg/mL for anti-p16, 1:75 and 0.006 mg/mL for anti-bcl-
2, 1:100 and 0.01 mg/mL for c-myc, 1: 50 and 0.01 mg/
mL for anti-Rb-1, 1:200 and 0.005 mg/mL for anti-ki67,
and 1:120 and 0.008 mg/mL for anti-EGFR antibodies.
The used dilution and concentration of the biotinylated
goat anti-mouse antibodies were 1:800 at final concentra-
tion 0.0025 mg/mL.
Immunohistochemistry procedure
The procedure of IHC was conducted according to the
manufacturer instructions (LSAB2 Universal Dakocyto-
mation strepavidin-biotin detection system). After baking
slides in oven at 65°C overnight, slides were deparaffin-
ized by applying sequential immersion for 5 min in
xylene, 95% ethanol, 70% ethanol, and distilled water
(DW). Autoclave-based antigen retrieval was standardized
for each target protein. Slides were placed in a jar contain-
ing antigen retrieval solution (0.1 M citrate buffer from
BDH at pH 6) and left in autoclave, for 0.5–8 min (varia-
ble time for each target protein) at 121°C. 100 μL of the
diluted primary antibodies were then applied onto the
sections and the slides were incubated in a humid cham-
ber overnight at 4°C.
The next day, slides were rinsed gently with PBS (Merck)-
Tween (Sigma) and placed in fresh PBS-Tween bath for 1
min. One-two drops of the diluted biotinylated secondary
goat anti-mouse antibodies (DakoCytomation) were
applied onto the sections and the slides were incubated in
a humid chamber for 1 h at 37°C. After rinsing step, One-
two drops of streptavidin-Horseradish peroxidase reagent
(DakoCytomation) was applied onto the sections, slides
were incubated for 30 min at 37°C. The prepared DAB-
substrate chromogen solution was applied onto sections,
Slides were incubated in dark at room temperature for 20
min. Mayer's hematoxylin stain was used as counterstain,
then slides were dehydrated and mounted with DPX
mounting fluid. In every run, two negative controls wereJournal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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used. The first negative control was antibody diluting
buffer added alone without primary antibodies. This is
essential for measuring the non-specific noise of staining.
The second negative control was a known normal urothe-
lium section devoid of any positive staining of the corre-
sponding target molecule. On the other hand, a strong
and consistently stained section was used as a positive
control for each target. The detected staining noise, if any,
was subtracted from the corresponding test section.
Staining analysis
The tumor cell staining, membranous, cytoplasmic, and
nuclear compartments were taken into consideration. Fur-
thermore, staining of the stromal cells dispersed between
tumor epithelial cells (not more than 5% of the total cells
in the section) was taken into account as these cells
reflected the same mutational abnormality of the epithe-
lial cells. However, other stromal cells scattered through-
out the section were not taken into account. The pattern
of staining was dominantly nuclear for p53, p16, Rb, and
bcl-2, nuclear and cytoplasmic for ki-67, cytoplasmic and
membranous for EGFR, and mainly cytoplasmic for c-
myc. Since differences in the staining intensity of the stud-
ied proteins were slight, the qualitative positive/negative
system was used. The immunostained cells at moderate to
intense dark brown color were considered positive while
other cells were considered negative (Figure. 1). Under
light microscope, the mean percentage of the positively
stained cells in each section was calculated from 3 dense,
medium, and light staining areas. In each area, the per-
centage of brown stained cells was calculated out of total
countable cells in 5 high power fields. Due to the numer-
ous, sometimes contradicting, scoring systems of the tar-
get proteins, the mean percentage of the positively stained
cells was quantitively compared among the different
groups of this study. To keep the scientific fidelity and to
ensure the impartial evaluation, the immunostained
slides were examined blindly by two scientists, one from
the research team and a consultant histopathologist out-
side the research team.
Statistical Analysis
Statistical analysis was conducted using SPSS software ver-
sion 10 and MS Excel 2000. Chi-square test of independ-
ence was used for evaluating the significant association of
histopathology type, tumor grade, tumor invasiveness,
disease staging, and disease recurrence with SBT and NSBT
groups. After proving that the studied groups obey the
normal distribution pattern by using Kolmogorov and
Semirnov normalization tests, parametric tests were used.
Accordingly, student t test was used to measure the signif-
icant difference of the mean percentage of the positively
stained cells for p53, p16, Rb, bcl-2, ki-67, c-myc, and
EGFR proteins among the different groups of the study.
Moreover, Pearson's correlation coefficient (r) was used to
measure the correlating behavior of the studied markers
with each other. P value less than 0.05 was considered as
significant.
Results
Demographic features of the bladder cancer and cystitis 
patients
The demographic features of the involved patients with
bladder cancer and chronic cystitis are summarized in
(Table 1). It was found that the mean age of SBT and SC
were less than of NSBT and NSC receptively (P < 0.05).
Male: female ratio was higher in SBT and SC than in NSBT
and NSC respectively (P < 0.05). On the other hand, there
was no significant difference between bladder cancer, as a
whole, and cystitis patients regarding mean age and sex
ratio (P > 0.05). Moreover, there was no significant differ-
ence in age and sex ratio in relation to tumor histopathol-
ogy, disease stage and presentation, tumor grade, tumor
invasion, or the tumor growth pattern in both SBT and
NSBT groups (P > 0.05).
Molecular profile among SBT, NSBT, SC, NSC, and CTL 
groups
The immunostaining of the paraffin-embedded sections
in terms of mean percentage of the positively stained cells
for p53, p16, bcl-2, ki-67, Rb, c-myc, and EGFR proteins
was compared among SBT, NSBT, SC, NSC, and CTL
groups. It was shown that the molecular profiles of SBT
and NSBT were different from each other and from that of
SC, NSC and CTL groups.
The mean percentage of the positively stained cells for p53
protein was higher in SBT than in NSBT (P < 0.05) and
both SBT and NSBT showed higher p53 expression than in
SC and NSC groups (P < 0.05) which both showed close
levels of p53 expression (P > 0.05). However, SC and NSC
showed higher levels of p53 than in CTL group (P < 0.05)
(Figure. 2-A). P16 level of expression was almost similar
among CTL, SC, and NSC groups (P > 0.05) while its level
sharply decreased in both SBT and NSBT (P < 0.05) with-
out any difference between SBT and NSBT (P > 0.05) (Fig-
ure. 2-B). Bcl-2 level of expression was higher in SBT than
in NSBT (P < 0.05) and both showed higher bcl-2 expres-
sion than in SC and NSC (P < 0.05). The bcl-2 level was
not different between SC and NSC (P > 0.05) which both
showed higher expression than in CTL group (P < 0.05)
(Figure. 2-C). Ki-67 expression was increasing from CTL
towards SC and NSC (P < 0.05) and from SC and NSC
towards SBT and NSBT (P < 0.05) without any significant
difference between SC and NSC or between SBT and NSBT
(P > 0.05) (Figure. 2-D). The level of c-myc in both SC and
NSC was not higher than in CTL group (P > 0.05) but it
was remarkably higher in SBT and NSBT than other
groups (P < 0.05). Interestingly, c-myc was higher in SBT
than in NSBT (P < 0.05) (Figure. 2-E). The expression ofJournal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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Immunohistochemical staining of bladder tumor sections Figure 1
Immunohistochemical staining of bladder tumor sections. Immunostaining by peroxidase/DAB (brown) counter-
stained with hematoxylin. (A) SCC SBT, c-myc protein cytoplasmic staining in high grade tumor (X400). (B) SCC SBT, EGFR 
cytoplasmic staining in high grade tumor (X1000). (C) TCC NSBT, bcl-2 nuclear staining high-grade tumor (X400). (D) TCC 
NSBT, Rb nuclear staining in invasive tumor (X1000). (E) TCC NSBT, ki-67 protein cytoplasmic staining in high-grade tumor 
(X400). (F) TCC SBT, p53 nuclear stains in low-grade tumor (X1000). (G) SC, p16 nuclear staining (X400). (H) NSC, c-myc 
cytoplasmic staining (X200).
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Table 1: The demographic features of the involved patients with baldder cancer and chronic cystitis.
Demographic feature Value
Bladder cancer
Number of patients:
SBT 45 (53.57%)
NSBT 39 (46.43%)
Sex of patients:
SBT 38 men and 7 women
NSBT 25 men and 14 women
Recurrence of bladder cancer:
First presentation 61 (72.62%)
Recurrent 23 (27.38%)
Age of patients:
SBT Range: 38–64 years, mean: 51.4 ± 6.2 years
NSBT Range: 46–72, mean: 66.5 ± 5.3 years
Type of tumor growth:
SBT 37 papillary
8 sessile
NSBT 34 papillary
4 sessile
1 nodular
Tumor muscle invasiveness:
Invasive (T2, T3, and T4) 62 (73.81%) patients
Non invasive (Ta, T1, and CIS) 22 (26.19%) patients
Grading:
Low grade (grade 1 and 2) 35 (41.66%) patients
High grade (grade 3) 49 (58.33%) patients
Histopathology of bladder tumors:
SCC 52 (61.91%) patients
TCC 32 (38.09%) patients
Staging of bladder cancer patients:
Stage I 9 (10.71%)
Stage II 13 (15.47%)
Stage III 18 (21.42%)
Stage IV 44 (52.38%)
Chronic cystitis
Number of patients:
SC 16 (36.36%)
NSC 28 cases (63.64%)
Sex of patients:
SC 14 men and 2 women
NSC 15 men and 13 women
Age of patients:
SC mean age 62.5 ± 3.5 years
NSC mean age 53.4 ± 4.2 yearsJournal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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The mean percentage of the positively immunostained cells for (A) p53, (B) p16, (C) bcl-2, (D) ki-67, (E) c-myc, (F) Rb, (G)  EGFR in bladder tissue sections of SBT, NSBT, SC, NSC, and CTL groups Figure 2
The mean percentage of the positively immunostained cells for (A) p53, (B) p16, (C) bcl-2, (D) ki-67, (E) c-
myc, (F) Rb, (G) EGFR in bladder tissue sections of SBT, NSBT, SC, NSC, and CTL groups.
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Rb was diminished in both SBT and NSBT when com-
pared with CTL, SC, and NSC groups (P < 0.05). NSBT
group showed lower Rb expression than in SBT group (P
< 0.05). Rb level in both SC and NSC was close and not
significantly different from that in CTL group (P > 0.05)
(Figure. 2-F). The expression level of EGFR increased sig-
nificantly from CTL group towards NSC, SC, NSBT, and
SBT (P < 0.05) (Figure. 2-G).
The clinicopthological features in SBT versus NSBT
The clinicopathological criteria in SBT and NSBT groups
were compared with each other using chi square test for
independence. It was found that SBT was associated with
SCC rather than TCC, high grade tumors rather than low
grade, and invasive tumors rather than non-invasive
tumors (P < 0.05). On the other hand, NSBT was associ-
ated with TCC rather than SCC, lower grade tumors rather
than high grade, and non-invasive rather than invasive
tumors (P < 0.05). However, there was no association
between SBT or NSBT and disease staging or presentation
(P > 0.05) (Table 2). Moreover, there was no association
between SBT or NSBT and the growth pattern of tumors
(data not shown).
The molecular profile of SBT and NSBT in regard to 
clinicopathological criteria
The mean percentages of the positively stained cells for
p53, p16, bcl-2, ki-67, c-myc, Rb, and EGFR proteins were
calculated with respect to the clinicopathological criteria
of SBT and NSBT. This served to understand the behavior
of the studied tumor suppressor proteins, oncogenes, pro-
liferative and apoptotic markers in relation to histopa-
thology, grade, invasiveness, disease staging, and
presentation.
Regarding SBT, p53, bcl-2, and EGFR were found higher
and Rb lower in SCC than in TCC (P < 0.05) (Figure. 3-A).
p53, bcl-2, p16, and c-myc were higher in high grade
tumors than low grade (P < 0.05) (Figure. 3-B). Bcl-2, ki-
67, c-myc, and EGFR were associated with invasive tumors
and the highest association was found in c-myc (P < 0.05)
(Figure. 3-C). P16 and Rb were severely lowered in late
stages of the disease (III and IV) while c-myc was
increased (P < 0.05) (Figure. 3-D). It was also found that
Rb and p16 were lowered in the recurrent presentation
while c-myc was higher in the first presentation (P < 0.05)
(Figure. 3-E).
Regarding NSBT, only p53 and c-myc were clearly associ-
ated with SCC while EGFR, unlike in SBT, was associated
with TCC (P < 0.05) (Figure. 4-A). All studied markers
were higher in high grade tumors than in low grade and
p16 was very low in high grade tumors (P < 0.05) (Figure.
4-B). Bcl-2, c-myc, and EGFR were higher in invasive than
in non-invasive tumors while p16 and Rb, unlike in SBT,
were lower in invasive than in non-invasive (P < 0.05)
(Figure. 4-C). Ki-67, c-myc, and EGFR were higher in late
stages of the disease than early stages while p16 and Rb
were lower in late than early stages (P < 0.05) (Figure. 4-
D). Bcl-2 was higher and p16 and Rb were lower in recur-
rent than in first presentation (P < 0.05) (Figure. 4-E).
The behavior of the studied markers in SBT and NSBT was
sometimes similar and sometimes different in relation to
the clinicopathological criteria. Collectively, in both SBT
and NSBT, the similar behavior of the studied markers was
as follows; a) p53 was associated with SCC. b) p53, bcl-2,
and c-myc were higher in high grade tumors. c) Bcl-2, c-
myc, and EGFR were higher in invasive than non-invasive
tumors. d) P16 and Rb were lowered in late stages of the
disease (III and IV) while c-myc was higher. e) Rb and p16
were lowered in the recurrent presentation.
On the other hand, the main lines of difference in the
expression of the studied markers between SBT and NSBT
were briefly as follows: a) In SBT, bcl-2, Rb, and EGFR
were associated with SCC while in NSBT c-myc was asso-
ciated with SCC and EGFR was associated with TCC. b) ki-
67, Rb, and EGFR were higher in high grade tumors in
NSBT rather than SBT. c) ki-67 was higher in invasive than
in non-invasive tumors in SBT while p16 and Rb were
lower in invasive than in non-invasive in NSBT. d) EGFR
and ki-67 were higher in late stages of the disease in NSBT
only. e) Bcl-2 in NSBT was higher in recurrent cases than
first time presentation.
Correlation coefficients among the studied markers
The Pearson's correlation coefficient (r) was calculated to
measure the correlating behavior among the different
studied markers in SBT and NSBT. Briefly, it was found
Table 2: The clinicopathological criteria in SBT versus NSBT
Criteria (N) SBT (45)
N (%)
NSBT (39)
N (%)
P value
Histopathology
SCC (52) 43 (82.69) 9 (17.3) < 0.05
TCC (32) 2 (6.25) 30 (3.75)
Tumor grade
High grade (49) 33 (67.34) 16 (32.65) < 0.05
Low grade (35) 12 (34.28) 23 (65.71)
Tumor invasiveness
Invasive (62) 38 (61.29) 24 (38.7) < 0.05
Non-invasive (22) 7 (31.81) 15 (68.18)
Tumor staging
Late stage (III and IV) (62) 31 (50) 31 (50) > 0.05
Early stage (I and II) (22) 14 (63.63) 8 (36.36)
Presentation
First presentation (61) 32 (52.45) 29 (47.54) > 0.05
Recurrent (23) 13 (56.52) 10 (43.47)Journal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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The mean percentage of the positively immunostained cells for p53, p16, bcl-2, ki-67, c-myc, Rb, and EGFR in tumor tissue sec- tions of SBT in relation to (A) histopathology; SCC and TCC Figure 3
The mean percentage of the positively immunostained cells for p53, p16, bcl-2, ki-67, c-myc, Rb, and EGFR in 
tumor tissue sections of SBT in relation to (A) histopathology; SCC and TCC. (B) Grade of the tumor; high and low 
grades. (C) Invasiveness of the tumor; invasive and non-invasive (D) Stage of cancer; late (stages VI and III) and early stages 
(stages I and II). (E) Presentation of the disease; first presentation and recurrent.
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The mean percentage of the positively immunostained cells for p53, p16, bcl-2, ki-67, c-myc, Rb, and EGFR in tumor tissue sec- tions of NSBT in relation to (A) histopathology; SCC and TCC Figure 4
The mean percentage of the positively immunostained cells for p53, p16, bcl-2, ki-67, c-myc, Rb, and EGFR in 
tumor tissue sections of NSBT in relation to (A) histopathology; SCC and TCC. (B) Grade of the tumor; high and 
low grades. (C) Invasiveness of the tumor; invasive and non-invasive. (D) Stage of cancer; late (stages VI and III) and early stages 
(stages I and II). (E) Presentation of the disease; first presentation and recurrent.
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that c-myc in both SBT and NSBT was inversely correlated
with p16, r = -0.74 and r = -0.68 respectively, and Rb, r = -
0.83 and r = -0.89 respectively (P < 0.05). p53 was posi-
tively correlated with bcl-2, r = +0.72, in SBT (P < 0.05)
but not in NSBT. EGFR was positively correlated with c-
myc in both SBT, r = +0.57, and NSBT, r = +0.61 (P <
0.05). And p16 was inversely correlated with p53 in SBT,
r = -0.59, and NSBT, r = -0.64 (P < 0.05).
Discussion
This study confirmed that the Middle East is greatly
affected by schistomiasis. In this study, SBT was 53.57% of
the involved cases of bladder cancer. In addition, the
mean age of SC and SBT patients was lower than in NSC
and NSBT respectively with significant male predomi-
nance in SBT and SC cases. This indicated that schistomal
infection speeds up the incidence of SC and SBT. This
finding was supported by another report which revealed
that the development of SBT occurs in younger age group,
49.4 years [7] and 51.4 years [19] where it affects males
predominantly.
SBT was associated significantly with SCC, high grade, and
invasive tumors while NSBT was associated with TCC, a
bit lower grade, and less invasive tumors. This provided
evidence that the molecular basis and the underlying
mechanisms of cancer development in SBT and NSBT
might be different. Regarding the association of SBT with
SCC, this study was congruous with other reports [6,19]
but this study showed that SBT is associated more with
high grade tumors and disagreed with other studies
[19,20] conducted in Egypt which revealed that SBT is
associated more with low grade tumors. Unfortunately no
studies were conducted in the same region of our study in
order to compare. Nevertheless, the possible explanation
of this variation might be attributed to the geographical
variation between the Nile river valley in Egypt and that in
Jordan, Syria and Iraq.
Alterations in cell cycle, oncogenic, and apoptotic pro-
teins are the key events in determining the biological
behavior of bladder cancer [21]. This study provided evi-
dence that the biological behavior between SBT and NSBT
and between SC/NSC and CTL groups was different. How-
ever, no remarkable differences were found between SC
and NSC groups. The expression level of the all studied
markers, except for p16 and ki-67 proteins, was different
between SBT and NSBT. p53, bcl-2, c-myc, Rb, and EGFR
proteins were significantly higher in SBT than in NSBT.
This could highlight the important targets of anticancer
therapy in SBT and NSBT. Surprisingly, the cystitis
patients, who were confirmed free of any premalignant
lesions, showed higher expression of p53, bcl-2, ki-67,
and EGFR but not c-myc, p16, and Rb proteins than in
CTL group. This provided a clue that both SC and NSC
might act as an intermediate stage between normal and
tumorous tissues indicating the danger of the long-lasing
inflammation of the bladder. Chronic cystitis appeared as
transitional phase for increasing cells turnover (ki-67),
decreasing tumor suppression capability (p53), decreas-
ing the apoptotic potential (bcl-2), and increasing the
cells' response to growth stimuli (EGFR) which all prepare
the suitable background of malignancy. On the other
hand, c-myc and Rb did not appear much affected during
the chronic cystitis phase.
The expression of p53 protein was higher in SBT than in
NSBT, higher in NSBT than in SC/NSC, and higher in SC/
NSC than in CTL. It was highly expressed in high grade
SCC in both SBT and NSBT. Therefore, p53 could be
exploited as a useful indicator for high grade SCC bladder
cancer in general and in SBT in particular. These results are
in agreement with other reports which showed that 72%
[22] and 73% [23] of the SBT cases expressed immunore-
active p53. In addition, the current study showed that the
higher the p53, the higher the grade of tumor. This is in
agreement with other reports showing that p53 was
detected in 75% of high grade bladder tumor and 25% of
low grade tumors [24] and p53 expression is higher in the
poorly differentiated SBT tumors [25]. The current study
did not show any association of p53 with disease staging
and presentation. This indicates that p53 is not a reliable
prognostic factor for both SBT and NSBT. This finding was
supported by a study [26] which stated that no evidence
has proved the reliability of p53 as prognostic factor in
bladder cancer. However, another report stated that p53 is
an independent prognostic factor in SCC and TCC blad-
der cancer [27].
Regarding p16, there was no difference in the expression
of p16 between SBT and NSBT but it was remarkably
lower in both SBT and NSBT than in SC, NSC, and CTL
groups. However, it was stated that p16 genes were altered
and deleted in schistosomal bladder cancer [12,28].
Unlike p53, p16 appeared as a reliable marker for assess-
ing the grade and invasiveness of NSBT rather than SBT. In
addition, p16 appeared to serve as a good prognostic fac-
tor in both SBT and NSBT. This study revealed clearly the
association of p16 with disease staging and presentation
which was strongly supported by another report [29]. This
study also showed that p16 is inversely correlated with
p53 indicating that the more mutated p53, the more over-
expression of dysfunctional p53, the less p16 proteins will
be transcribed.
Rb expression was severely diminished in NSBT and SBT
when compared to SC/NSC and CTL groups and was sig-
nificantly lower in NSBT than in SBT. In addition, Rb was
associated with SCC SBT, invasive NSBT, and late and
recurrent SBT and NSBT. Therefore, Rb protein can beJournal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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used as an efficient prognostic and discriminatory factor
for both SBT and NSBT. This might give a clue that schis-
tosomiasis has no particular relationship with Rb gene in
bladder cancer. There is a report [30] revealed that infre-
quent loss of Rb expression was found in invasive lesions
associated with schistosomiasis. Unfortunately, no previ-
ous study was done on the association of Rb with SBT in
the same geographical region of the current study. Inter-
estingly, both Rb and p16 proteins were inversely corre-
lated with c-myc in both SBT and NSBT. A recent study
[31] found that the mechanism of Rb inactivation is
through hyperphosphorylation, which results from loss of
p16 expression.
Bcl-2 protein was similar to that of p53. It was higher in
SBT than in NSBT, in SBT/NSBT than in SC/NSC, and in
SC/NSC than CTL. And it was associated with SCC SBT
and high grade invasive SBT and NSBT. Moreover, it was
not associated with staging, presentation or TCC NSBT.
Accordingly, bcl-2 proved to be a useful discriminatory
factor between SBT and NSBT, cystitis and bladder cancer,
and cancer/cystitis and CTL. This study showed that bcl-2,
or loss of apoptotic potential, increases steadily with blad-
der chronic inflammation and with bladder cancer favor-
ing SBT on NSBT. These findings are in agreement with
[24] who stated that the positive immunostaining of bcl-
2 was observed in 69% of bladder cancers where 75% of
patients were with high-grade tumors. In addition, the
current study supports a recent report [32] stating that bcl-
2 is of little prognostic value. However, our findings con-
tradict another report [23] which showed that bcl-2
expression was only 20% in schistosomal bladder cancer
and it has no relationship with tumor grade. On the other
hand, the current study confirmed the presence of signifi-
cant direct correlation between bcl-2 and p53 which sup-
ports the conclusions of another report [16] stating that
the loss of p53 function enhances the expression of bcl-2,
by relieving it from the transcriptional repression of the
wild type p53 protein.
Regarding oncogenes, c-myc was higher in SBT than in
NSBT, higher in SBT/NSBT than in other groups. It was
associated with tumor grade, invasiveness, and late stages
in both SBT and NSBT. It was the only factor associated
with tumor invasiveness, grade, and prognosis as well as it
proved to be a good discriminatory factor between SBT
and NSBT and between bladder cancer and cystitis/CTL
groups. These findings are in agreement with [33] who
showed that 58% of bladder cancer patients were c-myc
positive and 59% of the positive cases were of muscle-
invasive tumors. However unlike the results of our study,
they concluded that c-myc over-expression did not corre-
late with tumor grade or tumor progression while another
study [34] found that 34% of patients had positive c-myc
which was associated with tumor grade but with no prog-
nostic value. Unfortunately, no previous study was con-
ducted on the association of c-myc with SBT to compare
with. The current study might be the first to investigate the
role of c-myc in SBT and NSBT and might be the first to
relate c-myc with the clinicopathological criteria of blad-
der cancer.
Regarding EGFR, this oncogene increased significantly
from CTL towards NSC, SC, NSBT, and SBT. Therefore
EGFR could be used as a reliable discriminatory factor for
the all studied groups. Moreover, it was associated with
SBT SCC, NSBT TCC, high grade NSBT, invasive SBT and
NSBT, and late stages of NSBT. The results of the current
study are supported by a study [35] which stated that
EGFR is associated with SCC of bladder and another study
[10] stated that 70% of muscle-invasive bladder cancers
express EGFR which is associated with poor prognosis.
Accordingly, the current study showed the importance of
EGFR as a candidate for anti-cancer therapy in bladder. It
was suggested that there is a need to use anti-EGFR as a
novel anti-cancer therapy in bladder [11].
In cancer cells, Ki-67 plays an important role as an index
for the replication and the prognosis and is well associ-
ated to tumor grade, stage and recurrence [36]. In this
study, expression of Ki-67 protein was higher in SBT/
NSBT than in SC/NSC which was higher than in CTL
group. There was no difference in the proliferation rate
between SBT and NSBT. Therefore, a limited role of ki-67
might be present in schistosoma-related pathogenesis of
bladder cancers. Moreover, ki-67 was associated with high
grade NSBT, invasive SBT, and late stage NSBT. This is in
agreement with other studies [37,38] which showed that
Ki-67 positive immunostaining was correlated with tumor
grade and muscle invasion.
Conclusion
Taken together, the molecular background of SBT seems
distinct from that of NSBT. SBT was associated with SCC,
higher grade and more invasive tumors while NSBT was
associated with TCC, lower grade and less invasive
tumors. p53, bcl-2, c-myc, Rb, and EGFR were highly
expressed in SBT, more than in NSBT, which are therefore
might be useful as indicators and discriminatory markers
for bladder cancer in general and SBT in particular.
Chronic cystitis acts as an intermediate stage for the over-
expression of p53, bcl-2, and EGFR markers that were
shown implicated in both SBT and NSBT. p53 is strongly
associated with high grade SCC tumors in both SBT and
NSBT but it is poor prognostic factor. Bcl-2 is similar to
p53 but it is increased in recurrent cases. P16, Rb, and c-
myc were shown as good prognostic markers for SBT and
NSBT. C-myc and EGFR appeared central in many aspects
of carcinogenesis, tumor grade, tumor invasiveness, and
cancer staging.Journal of Experimental & Clinical Cancer Research 2009, 28:27 http://www.jeccr.com/content/28/1/27
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